Considering the encouraging results from in vitro experiments, further investigation of the CAR approach as a treatment option in antiviral therapy should be intensified, in particular after the approval of tisagenlecleucel as a successful CAR-based approach against CD19+ B-cell lymphoma. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.